125 related articles for article (PubMed ID: 15076134)
21. 707-AP peptide recognized by human antibody induces human leukocyte antigen A2-restricted cytotoxic T lymphocyte killing of melanoma.
Takahashi T; Irie RF; Nishinaka Y; Hoon DS
Clin Cancer Res; 1997 Aug; 3(8):1363-70. PubMed ID: 9815820
[TBL] [Abstract][Full Text] [Related]
22. Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.
Maeurer MJ; Chan HW; Karbach J; Salter RD; Knuth A; Lotze MT; Storkus WJ
Eur J Immunol; 1996 Nov; 26(11):2613-23. PubMed ID: 8921947
[TBL] [Abstract][Full Text] [Related]
23. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
[TBL] [Abstract][Full Text] [Related]
24. Modification of the HER2/NEU-derived tumor antigen GP2 improves induction of GP2-reactive cytotoxic T lymphocytes.
Tanaka Y; Amos KD; Joo HG; Eberlein TJ; Goedegebuure PS
Int J Cancer; 2001 Nov; 94(4):540-4. PubMed ID: 11745441
[TBL] [Abstract][Full Text] [Related]
25. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
Rivoltini L; Kawakami Y; Sakaguchi K; Southwood S; Sette A; Robbins PF; Marincola FM; Salgaller ML; Yannelli JR; Appella E
J Immunol; 1995 Mar; 154(5):2257-65. PubMed ID: 7868898
[TBL] [Abstract][Full Text] [Related]
26. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
[TBL] [Abstract][Full Text] [Related]
27. Recognition of human melanoma cells by HLA-A2.1-restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes.
Slingluff CL; Cox AL; Henderson RA; Hunt DF; Engelhard VH
J Immunol; 1993 Apr; 150(7):2955-63. PubMed ID: 7681084
[TBL] [Abstract][Full Text] [Related]
28. Peptide FLNPDVLDI of heparanase is a novel HLA-A2-restricted CTL epitope and elicits potent immunological antitumor effects in vitro with an 8-branched design.
Zhang J; Yang J; Fan D; Tao H; Wang H; Yu T
Oncol Rep; 2013 May; 29(5):1955-61. PubMed ID: 23503586
[TBL] [Abstract][Full Text] [Related]
29. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens.
Herr W; Schneider J; Lohse AW; Meyer zum Büschenfelde KH; Wölfel T
J Immunol Methods; 1996 May; 191(2):131-42. PubMed ID: 8666832
[TBL] [Abstract][Full Text] [Related]
30. Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells.
Ramakrishna V; Ross MM; Petersson M; Gatlin CC; Lyons CE; Miller CL; Myers HE; McDaniel M; Karns LR; Kiessling R; Parmiani G; Flyer DC
Int Immunol; 2003 Jun; 15(6):751-63. PubMed ID: 12750359
[TBL] [Abstract][Full Text] [Related]
31. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100.
Skipper JC; Kittlesen DJ; Hendrickson RC; Deacon DD; Harthun NL; Wagner SN; Hunt DF; Engelhard VH; Slingluff CL
J Immunol; 1996 Dec; 157(11):5027-33. PubMed ID: 8943411
[TBL] [Abstract][Full Text] [Related]
32. Generation of human tumor-specific CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors.
Gritzapis AD; Sotiriadou NN; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2004 Nov; 53(11):1027-40. PubMed ID: 15164233
[TBL] [Abstract][Full Text] [Related]
33. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity.
Yang S; Linette GP; Longerich S; Haluska FG
J Immunol; 2002 Jul; 169(1):531-9. PubMed ID: 12077285
[TBL] [Abstract][Full Text] [Related]
34. HLA-A2-restricted cytotoxic T lymphocyte epitopes from human hepsin as novel targets for prostate cancer immunotherapy.
Guo J; Li G; Tang J; Cao XB; Zhou QY; Fan ZJ; Zhu B; Pan XH
Scand J Immunol; 2013 Sep; 78(3):248-57. PubMed ID: 23721092
[TBL] [Abstract][Full Text] [Related]
35. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.
Harao M; Hirata S; Irie A; Senju S; Nakatsura T; Komori H; Ikuta Y; Yokomine K; Imai K; Inoue M; Harada K; Mori T; Tsunoda T; Nakatsuru S; Daigo Y; Nomori H; Nakamura Y; Baba H; Nishimura Y
Int J Cancer; 2008 Dec; 123(11):2616-25. PubMed ID: 18770861
[TBL] [Abstract][Full Text] [Related]
36. Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100.
Skipper JC; Gulden PH; Hendrickson RC; Harthun N; Caldwell JA; Shabanowitz J; Engelhard VH; Hunt DF; Slingluff CL
Int J Cancer; 1999 Aug; 82(5):669-77. PubMed ID: 10417764
[TBL] [Abstract][Full Text] [Related]
37. Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and Tyrosinase genes: a study in an unselected group of HLA-A2.1-positive patients.
Spagnoli GC; Schaefer C; Willimann TE; Kocher T; Amoroso A; Juretic A; Zuber M; Luscher U; Harder F; Heberer M
Int J Cancer; 1995 Oct; 64(5):309-15. PubMed ID: 7591302
[TBL] [Abstract][Full Text] [Related]
38. Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide.
Valmori D; Gervois N; Rimoldi D; Fonteneau JF; Bonelo A; Liénard D; Rivoltini L; Jotereau F; Cerottini JC; Romero P
J Immunol; 1998 Dec; 161(12):6956-62. PubMed ID: 9862730
[TBL] [Abstract][Full Text] [Related]
39. Recognition of human renal cell carcinoma and melanoma by HLA-A2-restricted cytotoxic T lymphocytes is mediated by shared peptide epitopes and up-regulated by interferon-gamma.
Bernhard H; Maeurer MJ; Jäger E; Wölfel T; Schneider J; Karbach J; Seliger B; Huber C; Storkus WS; Lotze MT; Meyer zum Büschenfelde KH; Knuth A
Scand J Immunol; 1996 Sep; 44(3):285-92. PubMed ID: 8795723
[TBL] [Abstract][Full Text] [Related]
40. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]